Clinical characteristics of ocular myasthenia gravis and outcomes of secondary generalisation: a systematic review protocol
Source : https://bmjopen.bmj.com/content/12/9/e060259
Objective We aim to systematically assess the clinical characteristics of ocular myasthenia gravis (OMG) and report on the proportion of patients who develop secondary generalised myasthenia gravis (SGMG). Introduction OMG...
Objective: We aim to systematically assess the clinical characteristics of ocular myasthenia gravis (OMG) and report on the proportion of patients who develop secondary generalised myasthenia gravis (SGMG).
Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients
Source : https://www.frontiersin.org/articles/10.3389/fimmu.2022.968206/full
Myasthenia Gravis (MG) is mediated by autoantibodies against acetylcholine receptors that cause loss of the receptors in the neuromuscular junction. Eculizumab, a C5-inhibitor, is the only approved treatment for MG...
Conclusion/Relevance: To enable identification of MG patients that are likely to respond to C7 inhibition, we developed a patient stratification assay and showed in a small cohort of MG patients (n=19) that 63% had significant complement activation and C7-dependent loss of AChRs in this in vitro set up. This study provides validation of C7 as a...
Abdeg technology for the treatment of myasthenia gravis: efgartigimod drug experience
Source : https://www.tandfonline.com/doi/abs/10.1080/1744666X.2022.2106972?journalCode=ierm20
ABSTRACT Myasthenia gravis is characterized by fluctuating muscle weakness that improves with rest and worsens with effort or throughout the day. Efgartigimod is a human IgG1-derived Fc fragment modified at...
Expert Opinion: Efgartigimod was efficacious and safe for generalized myasthenia patients with AChR antibody-positive patients. These findings need to be confirmed in AChR antibody-negative patients, and long-term safety studies are currently ongoing.
SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature
Source : https://www.nmd-journal.com/article/S0960-8966(22)00650-2/fulltext
Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction (NMJ). MG has an incidence of 30 per million/year in adults but is rarer (1-5 per million/year) in...
Relevance: Here we report 7 cases of new-onset myasthenia gravis in timely association with SARS-CoV-2 vaccination, including the first paediatric case identified to date. We also reviewed the literature for other new-onset MG cases reported within 4 weeks of SARS-CoV-2 vaccination and discuss our findings in the context of altered...
Neurological outcomes of extended thymectomy for thymomatous myasthenia gravis: Subxiphoid vs. trans-sternal approaches
Source : https://www.frontiersin.org/articles/10.3389/fsurg.2022.973954/full
BackgroundThe subxiphoid approach has been widely used recently. However, there is little data focusing on neurological outcomes in patients with thymomatous myasthenia gravis (MG) who underwent subxiphoid thoracoscopic thymectomy.
Conclusions: In patients with Masaoka stage I and II thymoma who underwent thymectomy, with tumor size less than 5 cm and thymomatous MG, age ≦48 years and the subxiphoid approach were associated with a rapid improvement in clinical status.